---
$id: https://graph.org.ai/products/commodity/51202405
$type: Product
source: UNSPSC
code: "51202405"
title: "Certolizumab"
class: "51202400"
classTitle: "Immunosupressant antibodies"
family: "51200000"
familyTitle: "Immunomodulating drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Certolizumab

**UNSPSC Code**: 51202405
**Class**: [Immunosupressant antibodies](Immunosupressant antibodies.mdx)
**Family**: [Immunomodulating drugs](../Immunomodulating drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a monoclonal antibody, which generally arises as C19H30N5O8S(C2H4O)n(C2H4O)n, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G6ADW90R16. European Medicines Agency schedules Certolizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25456. The term CERTOLIZUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 3, 2004, list 52.) As of Q4 2014, CERTOLIZUMAB remains US FDA's Preferred Term for this commodity. Certolizumab bears US NLM identifiers UMLS ID CL430555 and NCI Concept Code C97947. SMILES: none.

